Abstract
Although classical mutations in genes such as PIK3CA and PTEN occur at a relatively low frequency in haematological malignancies, activation of PI3K signalling is often detected in these tumours. In some conditions, for example acute myeloid leukaemia (AML), this is due to activating mutations of upstream regulators such as the FLT3 tyrosine kinase or RAS. Primary tumour cells taken from patients with AML, acute lymphoblastic leukaemia, chronic lymphocytic leukaemia and multiple myeloma show varying levels of sensitivity to PI3K and mTOR inhibitors. The challenge now is to conduct high quality trials with novel agents that target these pathways to establish the level of clinical response and to identify those subsets of patients that are more likely to respond.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abubaker J, Bavi PP et al (2007) PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia 21(11):2368–2370
Agazie YM, Movilla N et al (2003) The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3. Oncogene 22(44):6909–6918
Aggerholm A, Gronbaek K et al (2000) Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders. Eur J Haematol 65(2):109–113
Agliano A, Martin-Padura I et al (2008) Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer 123(9):2222–2227
Ailles LE, Gerhard B et al (1999) Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood 94(5):1761–1772
Ali K, Bilancio A et al (2004) Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 431(7011):1007–1011
Ali K, Camps M et al (2008) Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo. J Immunol 180(4):2538–2544
Allavena P, Sica A et al (2008) The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 66(1):1–9
Ansell SM, Inwards DJ et al (2008) Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 113(3):508–514
Aster JC, Pear WS et al (2008) Notch signaling in leukemia. Annu Rev Pathol 3:587–613
Bai RY, Ouyang T et al (2000) Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 96(13):4319–4327
Banerjee L, Mansour M et al (2009) Combined blockade of PI3-kinase and mTOR synergizes with gamma-secretase inhibitors to induce a high level of cell death in T-cell acute lymphoblastic leukaemia cells with activated Notch signalling. Br J Haematol 145(Suppl 1):9–10
Baohua Y, Xiaoyan Z et al (2008) Mutations of the PIK3CA gene in diffuse large B cell lymphoma. Diagn Mol Pathol 17(3):159–165
Bardet V, Tamburini J et al (2006) Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry. Haematologica 91(6):757–764
Baumann P, Mandl-Weber S et al (2009) The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res 315(3):485–497
Bergsagel PL, Kuehl WM (2005) Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23(26):6333–6338
Bichi R, Shinton SA et al (2002) Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 99(10):6955–6960
Billottet C, Grandage VL et al (2006) A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 25(50):6648–6659
Billottet C, Banerjee L et al (2009) Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation. Cancer Res 69(3):1027–1036
Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3(7):730–737
Bowen DT, Frew ME et al (2005) RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood 106(6):2113–2119
Brachmann S, Fritsch C et al (2009) PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. Curr Opin Cell Biol 21(2):194–198
Brandts CH, Sargin B et al (2005) Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res 65(21):9643–9650
Burchert A, Wang Y et al (2005) Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 19(10):1774–1782
Caligaris-Cappio F, Ghia P (2008) Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol 26(27):4497–4503
Chang H, Qi XY et al (2006) Analysis of PTEN deletions and mutations in multiple myeloma. Leuk Res 30(3):262–265
Chiorazzi N, Ferrarini M (2006) Evolving view of the in-vivo kinetics of chronic lymphocytic leukemia B cells. Hematology Am Soc Hematol Educ Program 273–8:512
Collins SJ (2008) Retinoic acid receptors, hematopoiesis and leukemogenesis. Curr Opin Hematol 15(4):346–351
Collins RJ, Verschuer LA et al (1989) Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br J Haematol 71(3):343–350
Condliffe AM, Davidson K et al (2005) Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106(4):1432–1440
Cornillet-Lefebvre P, Cuccuini W et al (2006) Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110delta mutations. Leukemia 20(2):374–376
Cutillas PR, Khwaja A et al (2006) Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry. Proc Natl Acad Sci USA 103(24):8959–8964
Dal Col J, Zancai P et al (2008) Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood 111(10):5142–5151
Daley GQ, Van Etten RA et al (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247(4944):824–830
De Keersmaecker K, Lahortiga I et al (2008) In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia. Haematologica 93(4):533–542
Decker T, Sandherr M et al (2009) A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Ann Hematol 88(3):221–227
Delwel R, Dorssers L et al (1987) Human recombinant multilineage colony stimulating factor (interleukin-3): stimulator of acute myelocytic leukemia progenitor cells in vitro. Blood 70(1):333–336
Demarest RM, Ratti F et al (2008) It’s T-ALL about Notch. Oncogene 27(38):5082–5091
Druker BJ (2008) Translation of the Philadelphia chromosome into therapy for CML. Blood 112(13):4808–4817
Farag SS, Zhang S et al (2009) Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk Res 33(11):1475–1480
Feuring-Buske M, Gerhard B et al (2003) Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. Leukemia 17(4):760–763
Fielding AK, Rowe JM et al (2009) Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood 113(19):4489–4496
Flex E, Petrangeli V et al (2008) Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 205(4):751–758
Fonseca R, Barlogie B et al (2004) Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64(4):1546–1558
Fruman DA, Bismuth G (2009) Fine tuning the immune response with PI3K. Immunol Rev 228(1):253–272
Gale RE, Green C et al (2008) The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111(5):2776–2784
Gallay N, Dos Santos C et al (2009) The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia 23(6):1029–1038
Gao T, Furnari F et al (2005) PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18(1):13–24
Garrido SM, Appelbaum FR et al (2001) Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 29(4):448–457
Goldstone AH, Richards SM et al (2008) In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 111(4):1827–1833
Grandage VL, Gale RE et al (2005) PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 19(4):586–594
Graux C, Cools J et al (2004) Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 36(10):1084–1089
Grigorieva I, Thomas X et al (1998) The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp Hematol 26(7):597–603
Grulich AE, van Leeuwen MT et al (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370(9581):59–67
Gutierrez A, Sanda T et al (2009) High frequency of PTEN, PI3K and AKT abnormalities in T cell acute lymphoblastic leukemia. Blood 114(3):647–650
Haneline LS, White H et al (2006) Genetic reduction of class IA PI-3 kinase activity alters fetal hematopoiesis and competitive repopulating ability of hematopoietic stem cells in vivo. Blood 107(4):1375–1382
Hashemolhosseini S, Nagamine Y et al (1998) Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 273(23):14424–14429
Herling M, Patel KA et al (2006) TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia 20(2):280–285
Herling M, Patel KA et al (2008) High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood 111(1):328–337
Hu L, Shi Y et al (2003) Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 101(8):3126–3135
Huettner CS, Zhang P et al (2000) Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 24(1):57–60
Hummerdal P, Andersson P et al (2006) Absence of hot spot mutations of the PIK3CA gene in acute myeloid leukaemia. Eur J Haematol 77(1):86–87
Ihle NT, Powis G (2009) Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol Cancer Ther 8(1):1–9
Jorgensen HG, Holyoake TL (2007) Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem Soc Trans 35(Pt 5):1347–1351
Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9(4):239–252
Kang S, Denley A et al (2006) Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci USA 103(5):1289–1294
Kharas MG, Fruman DA (2005) ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 65(6):2047–2053
Kharas MG, Janes MR et al (2008) Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest 118(9):3038–3050
Kim N, Saudemont A et al (2007) The p110delta catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion. Blood 110(9):3202–3208
Kim MS, Jeong EG et al (2008) Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer 98(9):1533–1535
Knight ZA, Gonzalez B et al (2006) A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125(4):733–747
Kojima K, Shimanuki M et al (2008) The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 22(9):1728–1736
Lagneaux L, Delforge A et al (1998) Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 91(7):2387–2396
Laine J, Kunstle G et al (2000) The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell 6(2):395–407
Lanham S, Hamblin T et al (2003) Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 101(3):1087–1093
Larson Gedman A, Chen Q et al (2009) The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia 23(8):1417–1425
Leverrier Y, Okkenhaug K et al (2003) Class I phosphoinositide 3-kinase p110beta is required for apoptotic cell and Fcgamma receptor-mediated phagocytosis by macrophages. J Biol Chem 278(40):38437–38442
Liu TC, Lin PM et al (2000) Mutation analysis of PTEN/MMAC1 in acute myeloid leukemia. Am J Hematol 63(4):170–175
Longo PG, Laurenti L et al (2008) The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 111(2):846–855
Mahmoud IS, Sughayer MA et al (2008) The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias. Br J Cancer 99(3):488–490
Maira SM, Stauffer F et al (2009) PI3K inhibitors for cancer treatment: where do we stand? Biochem Soc Trans 37(Pt 1):265–272
Martinez N, Camacho FI et al (2003) The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 63(23):8226–8232
Mazurier F, Doedens M et al (2003) Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD-SCID mice reveals a new class of human stem cells. Nat Med 9(7):959–963
Mead AJ, Linch DC et al (2007) FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 110(4):1262–1270
Min YH, Cheong JW et al (2004) Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia. Cancer Res 64(15):5225–5231
Miyamoto K, Araki KY et al (2007) Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 1(1):101–112
Mohi MG, Boulton C et al (2004) Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 101(9):3130–3135
Narducci MG, Stoppacciaro A et al (1997) TCL1 is overexpressed in patients affected by adult T-cell leukemias. Cancer Res 57(24):5452–5456
Niedermeier M, Hennessy BT et al (2009) Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 113(22):5549–5557
Ouillette P, Erba H et al (2008) Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res 68(4):1012–1021
Palomero T, Sulis ML et al (2007) Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 13(10):1203–1210
Papakonstanti EA, Ridley AJ et al (2007) The p110delta isoform of PI 3-kinase negatively controls RhoA and PTEN. EMBO J 26(13):3050–3061
Papakonstanti EA, Zwaenepoel O et al (2008) Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages. J Cell Sci 121(pt 24):4124–4133
Park S, Chapuis N et al (2008) PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia 22(9):1698–1706
Patton DT, Garden OA et al (2006) Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J Immunol 177(10):6598–6602
Pearce DJ, Taussig D et al (2006) AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 107(3):1166–1173
Pekarsky Y, Koval A et al (2000) Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci USA 97(7):3028–3033
Pekarsky Y, Santanam U et al (2006) Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 66(24):11590–11593
Pene F, Claessens YE et al (2002) Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 21(43):6587–6597
Peponi E, Drakos E et al (2006) Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 169(6):2171–2180
Perentesis JP, Bhatia S et al (2004) RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia. Leukemia 18(4):685–692
Podar K, Chauhan D et al (2009) Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 23(1):10–24
Pui CH, Robison LL et al (2008) Acute lymphoblastic leukaemia. Lancet 371(9617):1030–1043
Puri KD, Doggett TA et al (2004) Mechanisms and implications of phosphoinositide 3-kinase delta in promoting neutrophil trafficking into inflamed tissue. Blood 103(9):3448–3456
Quentmeier H, Reinhardt J et al (2003) FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 17(1):120–124
Quentmeier H, Martelli MP et al (2005) Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia 19(10):1760–1767
Raje N, Kumar S et al (2004) Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 104(13):4188–4193
Randis TM, Puri KD et al (2008) Role of PI3Kdelta and PI3Kgamma in inflammatory arthritis and tissue localization of neutrophils. Eur J Immunol 38(5):1215–1224
Renneville A, Roumier C et al (2008) Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 22(5):915–931
Rizzieri DA, Feldman E et al (2008) A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 14(9):2756–2762
Rousselot P, Huguet F et al (2007) Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109(1):58–60
Rudelius M, Pittaluga S et al (2006) Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 108(5):1668–1676
San-Miguel J, Harousseau JL et al (2008) Individualizing treatment of patients with myeloma in the era of novel agents. J Clin Oncol 26(16):2761–2766
Sattler M, Verma S et al (2000) The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 275(32):24273–24278
Saudemont A, Okkenhaug K et al (2007) p110delta is required for innate immunity to transplantable lymphomas. Biochem Soc Trans 35(pt 2):183–185
Saudemont A, Garcon F et al (2009) p110gamma and p110delta isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease. Proc Natl Acad Sci USA 106(14):5795–5800
Savitskiy VP, Shman TV et al (2003) Comparative measurement of spontaneous apoptosis in pediatric acute leukemia by different techniques. Cytometry B Clin Cytom 56(1):16–22
Schiffer CA (2008) Molecular characterization of AML: a significant advance or just another prognostic factor? Best Pract Res Clin Haematol 21(4):621–628
Shi Y, Gera J et al (2002) Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 62(17):5027–5034
Shi Y, Yan H et al (2005) Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 4(10):1533–1540
Shimada Y, Maeda M et al (2003) Cell culture in esophageal squamous cell carcinoma and the association with molecular markers. Clin Cancer Res 9(1):243–249
Sillaber C, Mayerhofer M et al (2008) Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur J Clin Invest 38(1):43–52
Silva A, Yunes JA et al (2008) PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 118(11):3762–3774
Skorski T, Bellacosa A et al (1997) Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 16(20):6151–6161
Slupianek A, Nieborowska-Skorska M et al (2001) Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 61(5):2194–2199
Stockmann C, Doedens A et al (2008) Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456(7223):814–818
Sujobert P, Bardet V et al (2005) Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106(3):1063–1066
Tamburini J, Elie C et al (2007) Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood 110(3):1025–1028
Taussig DC, Miraki-Moud F et al (2008) Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 112(3):568–575
Tazzari PL, Tabellini G et al (2007) The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia 21(5):886–896
Teachey DT, Obzut DA et al (2006) The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 107(3):1149–1155
Teachey DT, Sheen C et al (2008) mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood 112(5):2020–2023
Teachey DT, Grupp SA et al (2009) Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol 145(5):569–580
Thompson JE, Conlon JP et al (2007) Enhanced growth of myelodysplastic colonies in hypoxic conditions. Exp Hematol 35(1):21–31
Ticchioni M, Essafi M et al (2007) Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a. Oncogene 26(50):7081–7091
Touw I, Pouwels K et al (1990) Interleukin-7 is a growth factor of precursor B and T acute lymphoblastic leukemia. Blood 75(11):2097–2101
Uddin S, Hussain AR et al (2006) Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 108(13):4178–4186
Virgilio L, Narducci MG et al (1994) Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci USA 91(26):12530–12534
Wee S, Jagani Z et al (2009) PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 69(10):4286–4293
Weng AP, Ferrando AA et al (2004) Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306(5694):269–271
Xu Q, Simpson SE et al (2003) Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102(3):972–980
Yazbeck VY, Buglio D et al (2008) Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol 36(4):443–450
Yee KW, Zeng Z et al (2006) Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12(17):5165–5173
Yilmaz OH, Valdez R et al (2006) Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441(7092):475–482
Young DC, Griffin JD (1986) Autocrine secretion of GM-CSF in acute myeloblastic leukemia. Blood 68(5):1178–1181
Zebedin E, Simma O et al (2008) Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance. Blood 112(12):4655–4664
Zenz T, Dohner K et al (2008) Chronic lymphocytic leukaemia and acute myeloid leukaemia are not associated with AKT1 pleckstrin homology domain (E17K) mutations. Br J Haematol 141(5):742–743
Zhang J, Choi Y et al (2003) Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway. Oncogene 22(40):6289–6295
Zhang J, Grindley JC et al (2006) PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441(7092):518–522
Zollinger A, Stuhmer T et al (2008) Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. Blood 112(8):3403–3411
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Khwaja, A. (2010). PI3K as a Target for Therapy in Haematological Malignancies. In: Rommel, C., Vanhaesebroeck, B., Vogt, P. (eds) Phosphoinositide 3-kinase in Health and Disease. Current Topics in Microbiology and Immunology, vol 347. Springer, Berlin, Heidelberg. https://doi.org/10.1007/82_2010_71
Download citation
DOI: https://doi.org/10.1007/82_2010_71
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-14815-6
Online ISBN: 978-3-642-14816-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)